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Abstract
Background: Diabetic kidney disease (DKD) is a major burden in elderly patients with type 2 diabetes (T2DM).
Low estimated glomerular filtration rate (eGFR+, < 60 mL/min/1.73 m2) and albuminuria (Alb+) are essential for
the diagnosis of DKD, but their association with clinical variables and quality of care may be influenced by ageing.
Methods: Here we investigated the association of clinical variables and quality of care measures with eGFR+ and
Alb+ in 157,595 T2DM individuals participating to the Italian Association of Clinical Diabetologists (AMD) Annals
Initiative, stratified by age.
Results: The prevalence of eGFR+ and Alb+ increased with ageing, although this increment was more pronounced
for low eGFR. Irrespective of age, both the eGFR+ and Alb + groups had the worst risk factors profile when compared
to subjects without renal disease, showing a higher prevalence of out-of target values of HbA1c, BMI, triglycerides, HDL-C,
blood pressure and more complex cardiovascular (CVD) and anti-diabetic therapies, including a larger use of insulin
In all age groups, these associations differed according to the specific renal outcome examined: male sex and smoking
were positively associated with Alb+ and negatively with eGFR+; age and anti-hypertensive therapies were more
strongly associated with eGFR+, glucose control with Alb+, whereas BMI, and lipid-related variables with both
abnormalities. All these associations were attenuated in the older (> 75 years) as compared to the younger
groups (< 65 years; 65–75 years), and they were confirmed by multivariate analysis. Notably, Q-score values < 15,
indicating a low quality of care, were strongly associated with Alb+ (OR 8.54; P < 0.001), but not with eGFR+.
Conclusions: In T2DM patients, the prevalence of both eGFR and Albuminuria increase with age. DKD is associated with
poor cardiovascular risk profile and a lower quality of care, although these associations are influenced by the type of renal
abnormality and by ageing. These data indicate that clinical surveillance of DKD should not be unerestimated in old
T2DM patients.
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Background
Kidney dysfunction is rising worldwide in parallel
with population ageing [1], being diagnosed in about
25% of people aged 65–74 years, and in > 50% of
those aged > 75 years [2]. Senescence is associated
with a progressive decline of estimated glomerular
filtration rate (eGFR) of about 1–2 ml/min per year,
depending on ethnic, genetic and environmental fac-
tors, which may limit renal reserve and make this
organ more susceptible to damage by several factors,
including type 2 diabetes mellitus (T2DM) [3–6].
T2DM is a progressive disease [7] whose prevalence
also increases with age [8], thus exposing elderly patients
to an increased risk of long-term diabetic complications,
including diabetic kidney disease (DKD).
Low eGFR and albuminuria are the central features for
the diagnosis of DKD, and they may be present together
in 12% of T2DM subjects or as isolated forms in 35% of
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them: 24% as albuminuria with preserved eGFR values,
and 11% as isolated low eGFR values (< 60 ml/min) [9].
In the large cohort of the Italian Association of
Clinical Diabetologists (AMD) Annals Initiative, we have
recently demonstrated that low eGFR and albuminuria
may have different associations with clinical variables
and risk factors for cardiovascular disease (CVD) [9].
However, in spite of the large prevalence of DKD
among elderly T2DM patients, it is still unclear whether
ageing modifies the associations of low eGFR and
albuminuria with CVD risk factors, a particularly rele-
vant issue when considering that DKD is associated with
an enormous CVD burden, even at older ages [10, 11].
Furthermore, quality of diabetes care should be
carefully considered in elderly patients with DKD, since
management of diabetes and its associated CVD risk
factors may be different at different ages.
Therefore, here we explored the prevalence of low eGFR
and albuminuria and their associations with CVD risk
factors and quality of care indicators in a large cohort
of T2DM patients participating to the AMD Annals
Initiative, stratified according to a wide age-range.
Methods
In the present report, we analyzed the data set of
electronic medical records, collected between 1 January
and 31 December 2011, from 157,595 patients with
T2DM followed-up at 207 diabetes centers included
in the Italian Association of Clinical Diabetologists
(AMD) Annals Initiative. Details on database and data
collection have been reported elsewhere [12–14]. Data
were collected and centrally analyzed anonymously,
and the results were internally approved by the AMD
Annals scientific committee. This initiative includes
measuring and monitoring of major metabolic labora-
tory parameters, anthropometric measures, systolic
and diastolic blood pressure (BP), as well as the use
of specific classes of cardiovascular drugs. In
particular, kidney function was assessed by serum
creatinine and urinary albumin excretion measure-
ments. eGFR was estimated for each patient using a
standardized serum creatinine assay and the CKD-EPI
formula. Increased urinary albumin excretion was
diagnosed as: i) microalbuminuria if UAE rate was
> 20 and ≤ 200 μg/min, or if urinary albumin-to-
creatinine ratio (ACR) was > 2.5 mg/mmol in men
and > 3.5 mg/mmol in women and ≤30 mg/mmol in
both genders, or if urinary albumin concentration was
> 30 and ≤300 mg/l; ii) macroalbuminuria if UAE rate
was > 200 μg/min, or if ACR was > 30 mg/mmol in
both genders, or if urinary albumin concentration was
> 300 mg/l. Albuminuria indicated patients with either
micro- or macroalbuminuria.
Quality of care assessment
Quality of care was assessed through a validate score,
the Q score [15, 16], which is calculated on a combin-
ation of process and outcome indicators, based on levels
and treatment of major CVD risk factors (HbA1c, blood
pressure, LDL-cholesterol and albuminuria), assigning
the highest score when the desired goals were attained,
whereas the lowest score was assigned when the patient
was not treated for the specific condition despite
elevated values or when the patient showed unsatisfac-
tory values despite the treatment. Overall, Q score
ranges between 0 and 40, with a higher score reflecting
better quality of care.
Statistical analysis
Data are given as mean values ± standard deviation
(SD); and categorical variables as frequencies and
percentages. Logistic mixed regression models were used
to analyze predictors of eGFR < 60 mL/min/1.73 m2 or
albuminuria. Due to the large sample size, odds ratios
(ORs) were displayed with 99.9% confidence interval
(CI). Diabetes clinics were fitted as random effect to
consider possible differences in data across centers.
Multivariate models were fitted with a complete-case
analysis by including patients for which all data were
observed. No missing data replacement was used. For
the high number of missing values, a separate multivari-
ate OR was computed for smoking status. The analyses
were made using STATA software, Version 14 (Stata-
Corp, College Station, Texas).
Results
Clinical characteristics of T2DM participants according to age
Clinical characteristics of the 157,595 T2DM subjects
according to age (< 65 yrs., 65–75 yrs., > 75 yrs) are
shown in Table 1. Male gender and smokers, as well as
BMI values decreased with age, whereas glucose control
was comparable (mean HbA1c 7.2–7.3%) in all age-
groups, in spite of the increasing diabetes duration.
eGFR values decreased, whereas serum creatinine
levels and the frequency of subjects with diabetic retin-
opathy increased with age. The oldest groups showed a
more favorable lipid profile, higher systolic and lower
diastolic BP values and lower proportion of smokers.
Age-differences were also noted in hypoglycaemic
therapies: diet therapy only and oral hypoglycaemic
drugs use progressively decreased with age, while insulin
treatment increased. In particular, in the > 75 years old
group, 59% of study subjects were treated with oral
drugs, 20% with insulin, 17% with a combination therapy
and 5% with diet alone.
As for cardiovascular medications, lipid-lowering treat-
ments were more frequently used in the intermediate age-
group, fibrates in the youngest subjects, although in a
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small absolute number, whereas anti-hypertensive and
aspirin treatments progressively increased across age-
strata.
Quality of care, assessed through the Q-score, showed
high values (mean score 30), indicative of an overall good
quality of care, with slightly lower scores in the oldest group.
Clinical characteristics of T2DM participants according to
age and the presence of low eGFR and albuminuria
As shown in Fig. 1, the prevalence of DKD progressively
increased with age, and this increment was more evident
for low eGFR than for albuminuria (P < 0.001 for all
comparisons).
Table 1 Baseline clinical characteristics by age groups
All < 65 years 65–75 years > 75 years
n = 157,595 n = 58,238 n = 56,682 n = 42,675
Male sex 89,290 (56.7%) 35,941 (61.7%) 32,469 (57.3%) 20,880 (48.9%)
Age (years) 68 ± 11 57 ± 7 70 ± 3 80 ± 4
Known duration of diabetes (years) 11 ± 9 8 ± 7 12 ± 9 15 ± 11
Serum creatinine (mg/dL) 0.98 ± 0.54 0.88 ± 0.43 0.99 ± 0.54 1.10 ± 0.63
eGFR (mL/min/1.73m2) 76 ± 21 89 ± 18 74 ± 18 62 ± 19
Retinopathy 22,250 (14.1%) 6998 (12.0%) 8773 (15.5%) 6479 (15.2%)
BMI (Kg/m2) 29.6 ± 5.3 30.4 ± 5.8 29.6 ± 5.1 28.4 ± 4.7
HbA1c (%) 7.2 ± 1.3 7.3 ± 1.4 7.2 ± 1.2 7.2 ± 1.2
HbA1c
7.0–7.4% 26,576 (17.1%) 9002 (15.7%) 10,057 (18.0%) 7517 (17.9%)
7.5–8.5% 32,320 (20.8%) 11,265 (19.7%) 11,473 (20.5%) 9582 (22.8%)
> 8.5% 20,993 (13.5%) 9214 (16.1%) 6401 (11.4%) 5378 (12.8%)
Total cholesterol (mg/dL) 177 ± 39 181 ± 40 175 ± 37 176 ± 38
Triglycerides (mg/dL) 137 ± 90 147 ± 108 133 ± 82 128 ± 69
HDL (mg/dL) 50 ± 14 48 ± 14 50 ± 14 51 ± 15
LDL (mg/dL) 101 ± 33 104 ± 34 99 ± 32 100 ± 33
Systolic BP (mmHg) 137 ± 18 134 ± 18 139 ± 18 140 ± 19
Diastolic BP (mmHg) 78 ± 9 79 ± 9 78 ± 9 76 ± 9
Smokers 14,793 (16.7%) 8865 (25.2%) 4435 (14.1%) 1493 (6.9%)
Cardiovascular therapy
Lipid-lowering treatment 90,690 (57.5%) 31,402 (53.9%) 35,490 (62.6%) 23,798 (55.8%)
Treatment with statins 83,342 (52.9%) 28,002 (48.1%) 32,928 (58.1%) 22,412 (52.5%)
Treatment with fibrates 4588 (2.9%) 2285 (3.9%) 1503 (2.7%) 800 (1.9%)
Antihypertensive treatment 112,424 (71.3%) 35,069 (60.2%) 43,031 (75.9%) 34,324 (80.4%)
Treatment with ACE-Is/ARBs 95,821 (60.8%) 30,460 (52.3%) 36,938 (65.2%) 28,423 (66.6%)
Aspirin 35,284 (22.4%) 9467 (16.3%) 14,278 (25.2%) 11,539 (27.0%)
Antidiabetic therapy
Diet 8229 (5.2%) 3149 (5.4%) 3086 (5.4%) 1994 (4.7%)
Oral antidiabetic drugs 100,535 (63.8%) 39,150 (67.2%) 36,379 (64.2%) 25,006 (58.6%)
Oral antidiabetic drugs and insulin 26,634 (16.9%) 9460 (16.2%) 9906 (17.5%) 7268 (17.0%)
Insulin 22,197 (14.1%) 6479 (11.1%) 7311 (12.9%) 8407 (19.7%)
Q Score 30 ± 8 30 ± 8 30 ± 8 29 ± 8
< 15 5935 (3.8%) 2534 (4.4%) 1808 (3.2%) 1593 (3.7%)
15–25 42,165 (26.8%) 15,375 (26.4%) 14,447 (25.5%) 12,343 (28.9%)
> 25 109,495 (69.5%) 40,329 (69.2%) 40,427 (71.3%) 28,739 (67.3%)
Mean ± SD or absolute frequency (percentage). ACE-Is = angiotensin converting enzyme-inhibitors, ARBs = angiotensin II receptor antagonists, BMI = body mass
index, BP = blood pressure, eGFR = estimated glomerular filtration rate, HbA1c = glycated hemoglobin, HDL = high-density lipoprotein cholesterol, LDL = low-density
lipoprotein cholesterol. Patients’ missing data: known duration of diabetes in 8435 (5.4%), BMI in 14,918 (9.5%), HbA1c in 2291 (1.5%), total cholesterol in 8127
(5.2%), triglycerides in 10,293 (6.5%), HDL-c in 12,812 (8.1%), LDL-c in 13,495 (8.6%), blood pressure in 16,009 24,106 (15.3%), and smoking status in 69,213 (43.9%)
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Clinical parameters according to age and the presence
of low eGFR (Table 2) or albuminuria (Table 3) were
also investigated.
As shown in Table 2, subjects in the eGFR+ (eGFR<
60 ml/min) groups showed a lower prevalence of men,
an older age and a longer diabetes duration. Albumin-
uria and retinopathy were also more prevalent in the
eGFR + groups, without differences across age-strata.
Similarly, irrespective of age, the percentage of out-of
target CVD risk factors were significantly higher in the
eGFR+ than in the eGFR- groups, with the exceptions of
BMI which did not show any difference according to
eGFR status in the oldest group, of BP control which
was comparable in the 65–75 group, of the percentage
of smokers, which was lower in the eGFR+ groups in all
age-strata, and LDL-C which was more at target in the
eGFR- group. Also, glucose control was worst in the
eGFR+ groups in all age strata and, overall, poorest in
the < 65 years group.
As for concomitant treatments, diet and oral medica-
tions decreased whereas insulin use alone or in combin-
ation with oral agents was higher in the eGFR+ groups;
also the percentage of subjects treated with lipid lower-
ing, anti-hypertensive drugs and aspirin was higher in
the eGFR+ groups, irrespectively of age.
The number of subjects with low Q-score (< 15, bad
quality of care), was higher in the eGFR+ groups at all
ages, whereas Q-score values > 25, indicating a good
quality of care, had the opposite trend.
Table 3 shows study parameters according to age and
the presence of albuminuria (Alb+). Prevalence of male
sex, age and diabetes duration were higher in the Alb+
group, irrespective of the age-categories. Also risk fac-
tors profile was worst in the Alb+ groups, which showed
higher BMI values, poorer glucose, TGs, HDL-C, BP
control and smoking habit; conversely, the Alb+ group
had a higher percentage of subjects with at-target LDL-
C values.
Lipid lowering and anti-hypertensive treatments
were more frequent in the Alb+ groups, although the
differences were not statistically significant at older
ages (> 75 years group). Similarly to the eGFR+
groups, more complex hypoglycemic therapies (insulin
alone or in combination) were more frequent in the
Alb+ groups at all ages.
The Q score showed consistently worst values in the
Alb+ groups at all ages; low Q-score values (< 15) were
particularly frequent in younger subjects with than with-
out albuminuria (11.2% vs 2%, respectively).
Factors associated with low eGFR and albuminuria
according to age
Univariate associations of low eGFR and albuminuria
with study variables according to age strata are illustrated
in Additional file 1: Figure S1.
Both eGFR and albuminuria showed significant associa-
tions with study variables, although with a different strength
and direction, depending on the examined outcome.
Impaired renal function (eGFR< 60 ml/min) was
significantly associated with age, diabetes duration, BMI,
TG/HDL-C, BP, anti-hypertensive and lipid-lowering
treatments, and the strength of these associations was
attenuated by ageing. Male sex and smoking habit were
negatively associated with low eGFR values. Also, higher
BP values (≥ 140/85 mmHg) were positively associated
with low eGFR in the < 65 years group and negatively in
the older ones.
Albuminuria was positively and strongly associated with
male sex, glucose control, TG/HDL-C, BP and medica-
tions, and smoking. BP control was positively associated
with albuminuria at every age-range. LDL-C was nega-
tively associated with the presence of albuminuria. Also in
Fig. 1 Proportion of patients with eGFR< 60 mL/min/1.73 m2 or albuminuria, by age groups
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Table 2 Patients’ characteristics by the presence of low estimated glomerular filtration and by age groups
< 65 years 65–75 years > 75 years
eGFR- eGFR+ eGFR- eGFR+ eGFR- eGFR+














Age (years) 56 ± 7 60 ± 5 < 0.001 70 ± 3 71 ± 3 < 0.001 80 ± 4 81 ± 4 < 0.001



























BMI (Kg/m2) 30.3 ± 5.7 31.8 ± 6.2 < 0.001 29.3 ± 5.0 30.5 ± 5.3 < 0.001 28.0 ± 4.6 28.8 ± 4.8 < 0.001
HbA1c (%) 7.3 ± 1.4 7.4 ± 1.5 < 0.001 7.1 ± 1.2 7.3 ± 1.3 < 0.001 7.2 ± 1.2 7.3 ± 1.3 < 0.001













































































































































































































































The bold values refers to significant (p < 0.001) comparisons between patients with eGFR< 60 mL/min/1.73m2 (eGFR+) and those with values
≥ 60 mL/min/1.73m2 (eGFR-)
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the case of albuminuria the strength of these associations
was generally attenuated in the oldest groups.
These relationships were confirmed at multivariate
analysis (Table 4). The model for eGFR includes sex,
age, BMI, glucose, lipid and BP control, and albuminuria.
The model testing albuminuria as dependent variable
also included eGFR. In particular, multivariate analysis
confirmed that glucose control was not an independent
predictor of low eGFR, and the association with BP con-
trol was attenuated in the youngest group (< 65 years).
As for smoking habit, it was independently and posi-
tively associated with albuminuria (OR 1.60; 95%CI:
1.52–1.68), whereas the opposite was noted for low
eGFR (OR 0.79; 95% CI 0.74–0.84).
Similarly, a low quality of diabetes care (Q score values
< 15 vs > 25) was strongly associated with albuminuria
(OR 8.54; P < 0.001), whereas this association was not
noted for low eGFR values (OR 1.10; P = 0.004), irre-
spective of age groups (Additional file 2: Figure S2).
Discussion
Diabetes care in elderly patients is challenging because of
several epidemiological, clinical and economic issues,
which are amplified in presence of chronic complications.
The prevalence of diabetes is high in older subjects, af-
fecting more than 20% of subjects > 65 years [17]. Our
data, on a large sample of outpatients with T2DM with a
wide age-range, showed that renal complications affect
41.3% of this population, and more than 60% of those
aged > 75 years.
These prevalence figures are comparable to those
reported both in non-diabetic and diabetic cohorts, al-
though with some disparities imputable to differences in
study design, disease duration, and T2DM management.
In non-diabetic cohorts, the prevalence of renal disease
parallels the ageing process, affecting up-to 56.1% of sub-
jects aged > 75 years [18–21]. However, the NHANES
study underlined how diabetes has a stronger impact on
renal function than ageing itself, showing that the increas-
ing prevalence of renal impairment in the US population
in the period 2005–2008 was related to the increasing
trends of diabetes, while the age distribution of that popu-
lation did not change during the observation [10].
Available data on DKD prevalence among elderly
T2DM cohorts are also varying, with a DKD prevalence of
15.1% reported in older adults in the Republic of Ireland
[22], whereas, in theT2DM patients aged > 75 years in the
ZODIAC-24 study [23], the prevalence of low eGFR was
42% and that of albuminuria 52%. These data are similar
to our findings and those reported in the Renal Insuffi-
ciency and Cardiovascular Events (RIACE) Italian Multi-
center Study (RIACE) cohort [24].
The overall high prevalence of DKD in elderly T2DM
patients is likely to be the result of two opposite
trajectories, i.e. the high frequency of T2DM in this age-
group, and the decreased mortality rate due to a better
control of the disease, which may have contributed to
increase patients survival, allowing sufficient time to
develop chronic diabetes complications [25–28].
The physiological decline of renal function with age may
have also played a role, since senescence is associated with
a gradual decline of eGFR [3, 4], an observation that was
confirmed by our study, wherein the impairment of eGFR
across age-strata was much more pronounced than the
occurrence of albuminuria (Fig. 1) .
Similarly, in the UK Prospective Diabetes Study
(UKPDS) study, older age was a significant predictor for
the onset of low eGFR but not of albuminuria, whose
prevalence was comparable to our findings: 24.9% in the
UKPDS vs. 25.6% in our study subjects in the corre-
sponding age-range (< 65 years old) [29, 30].
Interestingly, our data also show that not all T2DM
patients will eventually develop renal impairment even at
very old age; indeed a large group of subjects aged >
75 years (n = 16.984, 48.5%) were still normo-albuminuric
with preserved eGFR values, thus confirming that DKD in
elderly patients is not only consequent to the loss of renal
function of the ageing kidney. Furthermore, elderly sub-
jects without DKD (mean age 80 years, diabetes duration
14 years) showed an optimal glucose control (mean
HbA1c 7.1%), with lipid and BP values close to recom-
mended targets and no weight loss, indicating the import-
ance of controlling major risk factors in order to prevent
renal complications even late in life.
CVD risk factors control is another important issue in
elderly patients, especially in those with DKD. Thus, the
health and economic burden associated with DKD is
largely related to the high risk for CVD morbidity and
mortality and its evolution to end stage renal disease
[31–34], which does not spare the elderly population
[10, 11]. In the Atherosclerosis Risk in Communities
(ARIC) Study, both eGFR and albuminuria were associ-
ated with CVD outcomes, although age and other demo-
graphic variables had a modulating effect on these
associations [10]. Furthermore, other studies and recent
meta-analyses confirmed that the relationship between
renal function and CVD mortality is largely consistent
across age-categories [35–38].
Accordingly, our data show that both low eGFR and
albuminuria are associated with a worst CVD risk
factors profile in all the considered age-groups, and this
was also evident for parameters such as BMI, triglycer-
ides and smoking habit that progressively decrease at
older age.
Our data also confirm that, independently of age,
the strength of the associations of CVD risk factors is
different when considering low eGFR and albumin-
uria, as previously demonstrated in our and in other
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cohorts [9, 24, 30]. These differences were particularly
evident for gender, BP and glucose control.
Gender has been reported to have consistent and spe-
cific associations with DKD features, with potential im-
plications in terms of CVD risk [39–41]. As expected, in
the overall population, female gender was more preva-
lent at older ages, likely because of the female survival
advantage. However, gender differences in DKD were
maintained even at older age, with T2DM women being
more prevalent in the low eGFR group, and men in the
albuminuric group.
This finding is in line with several reports showing
gender- differences in renal disease both in non-diabetic
[42, 43] and diabetic cohorts [9, 29, 44]. Consistent with
our findings of male gender being a risk factor for
albumuminuria, in the UKPDS (The United Kingdom
Prospective Diabetic Study) male gender was a predictor
for the incidence of albuminuria, but not of low eGFR
values [29]. Similarly, both in the RIACE study [44] and
in previous reports from the AMD Annals Initiative [9],
the albuminuric phenotype was more frequent in T2DM
men, whereas the low eGFR phenotype was more preva-
lent in women. Furthermore, male gender seems to be a
risk factor for DKD progression towards ESRD [45–49],
whereas once on dialysis treatment, mortality risk seems
to be higher in the female T2DM population [50–53].
Table 3 Patients’ characteristics by the presence of albuminuria and by age groups
< 65 years 65–75 years > 75 years
ALB- ALB+ ALB- ALB+ ALB- ALB+
n = 43,352 n = 14,886 p n = 40,556 n = 16,126 p n = 28,300 n = 14,375 p
Male sex 25,532 (58.9%) 10,409 (69.9%) < 0.001 21,651 (53.4%) 10,818 (67.1%) < 0.001 12,721 (45.0%) 8159 (56.8%) < 0.001
Age (years) 56 ± 7 57 ± 7 < 0.001 70 ± 3 70 ± 3 < 0.001 80 ± 4 81 ± 4 < 0.001
Duration of
diabetes (years)
8 ± 7 9 ± 8 < 0.001 12 ± 9 13 ± 9 < 0.001 14 ± 11 16 ± 11 < 0.001
eGFR < 60 mL/min/1.73m2 2086 (4.8%) 1855 (12.5%) < 0.001 7304 (18.0%) 5000 (31.0%) < 0.001 11,316 (40.0%) 7605 (52.9%) < 0.001
Retinopathy 4346 (10.0%) 2652 (17.8%) < 0.001 5357 (13.2%) 3416 (21.2%) < 0.001 3729 (13.2%) 2750 (19.1%) < 0.001
BMI (Kg/m2) 30.1 ± 5.7 31.1 ± 5.9 < 0.001 29.4 ± 5.1 30.0 ± 5.1 < 0.001 28.3 ± 4.7 28.5 ± 4.7 < 0.001
HbA1c (%) 7.2 ± 1.4 7.6 ± 1.6 < 0.001 7.1 ± 1.2 7.4 ± 1.3 < 0.001 7.1 ± 1.2 7.4 ± 1.3 < 0.001
Triglycerides ≥150 mg/dl 13,144 (32.0%) 6152 (43.7%) < 0.001 10,438 (27.4%) 5256 (34.9%) < 0.001 6453 (24.8%) 4024 (30.7%) < 0.001
HDL < 40/< 50 mg/dL
(Male/Female)
15,038 (37.3%) 6165 (44.4%) < 0.001 12,114 (32.4%) 5605 (37.9%) < 0.001 8308 (32.5%) 4878 (38.0%) < 0.001
LDL ≥100 mg/dL 21,368 (53.4%) 6674 (49.1%) < 0.001 17,237 (46.0%) 6306 (42.8%) < 0.001 12,048 (47.3%) 5662 (44.2%) < 0.001
Blood Pressure
≥ 140/85 mmHg
16,778 (45.2%) 7324 (56.3%) < 0.001 18,392 (53.4%) 8762 (62.8%) < 0.001 12,690 (55.1%) 7516 (63.2%) < 0.001




22,567 (52.1%) 8835 (59.4%) < 0.001 24,821 (61.2%) 10,669 (66.2%) < 0.001 15,504 (54.8%) 8294 (57.7%) 0.072
Treatment with statins 20,167 (46.5%) 7835 (52.6%) < 0.001 23,040 (56.8%) 9888 (61.3%) < 0.001 14,616 (51.6%) 7796 (54.2%) 0.217
Treatment with fibrates 1616 (3.7%) 669 (4.5%) < 0.001 1058 (2.6%) 445 (2.8%) 0.045 508 (1.8%) 292 (2.0%) 0.175
Antihypertensive
treatment





21,042 (48.5%) 9418 (63.3%) < 0.001 25,256 (62.3%) 11,682 (72.4%) < 0.001 18,282 (64.6%) 10,141
(70.5%)
< 0.001
Aspirin 6536 (15.1%) 2931 (19.7%) < 0.001 9751 (24.0%) 4527 (28.1%) < 0.001 7468 (26.4%) 4071 (28.3%) 0.010
Antidiabetic therapy
Diet 2596 (6.0%) 553 (3.7%) < 0.001 2445 (6.0%) 641 (4.0%) < 0.001 1502 (5.3%) 492 (3.4%) < 0.001
Oral antidiabetic drugs 29,916 (69.0%) 9234 (62.0%) < 0.001 27,180 (67.0%) 9199 (57.0%) < 0.001 17,437 (61.6%) 7569 (52.7%) < 0.001
Oral drugs and insulin 6320 (14.6%) 3140 (21.1%) < 0.001 6365 (15.7%) 3541 (22.0%) < 0.001 4416 (15.6%) 2852 (19.8%) < 0.001
Insulin 4520 (10.4%) 1959 (13.2%) < 0.001 4566 (11.3%) 2745 (17.0%) < 0.001 4945 (17.5%) 3462 (24.1%) < 0.001
Q Score
< 15 864 (2.0%) 1670 (11.2%) < 0.001 541 (1.3%) 1267 (7.9%) < 0.001 449 (1.6%) 1144 (8.0%) < 0.001
15–25 9847 (22.7%) 5528 (37.1%) < 0.001 8829 (21.8%) 5618 (34.8%) < 0.001 6948 (24.6%) 5395 (37.5%) < 0.001
> 25 32,641 (75.3%) 7688 (51.6%) < 0.001 31,186 (76.9%) 9241 (57.3%) < 0.001 20,903 (73.9%) 7836 (54.5%) < 0.001
The bold values refers to significant (p < 0.001) comparisons between patients with albuminuria (ALB+) and those with normoalbuminuria (ALB -)
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In spite of these epidemiological findings, the patho-
physiological bases of these gender differences remain
still largely unknown, although it should be kept in mind
that formulas commonly used for eGFR calculation are
influenced by gender [54, 55].
Worst glucose and BP control were also associated
with both low eGFR and albuminuria, irrespective of age
and in spite of the overall mean at- target values in all
age-groups, confirming the undisputed role of intensive
control of these risk factors in the prevention of micro-
vascular disease. However, at multivariate analysis, the
association with HbA1c values remained significant for
albuminuria only; the impact of BP values on the risk of
low eGFR was attenuated in the oldest group, suggesting
that the network of factors related to eGFR decline in
T2DM subjects is more complex.
Notably, although glucose control was overall good in
all age-groups (mean HbA1c 7.2%), a larger percentage
of subjects in the youngest group showed out-of-target
HbA1c values (> 8.5%), compared to subjects > 65 years,
whereas the higher prevalence of HbA1c between 7.5–
8.5% at older age in our cohort could be interpreted in
the light of current guidelines that suggest to mitigate
glucose targets in the elderly [28, 38].
Age had an influence on these associations, attenuat-
ing the relationship between renal features and the ex-
amined CVD risk factors. This was particularly evident
for BP control and anti-hypertensive treatments, that
were positively and strongly associated with low eGFR
values in the < 65 years group and progressively less at
older ages. Also smoking habit, that was positively asso-
ciated with albuminuria and negatively with low eGFR
was influenced by age.
When evaluating quality of diabetes care, through
the Q score [15, 16], we found an overall good quality
of care (mean values of 29–30) at different age- and
DKD strata, and these data are in line with the findings
of other diabetic cohorts in Italy [15, 16]. However,
older subjects (> 75 years) and those with albuminuria
(Alb+) showed lower Q score values compared to the
Table 4 Multivariate odds ratios for estimated glomerular filtration rate < 60 mL/min/1.73 m2 or albuminuria by age groups
Overall p < 65 years p 65–75 years p > 75 years p
Model for eGFR < 60 mL/min/1.73 m2
Male sex 0.85 (0.82–0.88) < 0.001 0.83 (0.76–0.90) < 0.001 0.84 (0.80–0.88) < 0.001 0.86 (0.82–0.91) < 0.001
Age (×5 years) 1.81 (1.79–1.83) < 0.001 1.75 (1.67–1.82) < 0.001 1.90 (1.82–1.99) < 0.001 1.77 (1.72–1.83) < 0.001
BMI (× 5 Kg/m2) 1.19 (1.17–1.21) < 0.001 1.13 (1.09–1.17) < 0.001 1.18 (1.15–1.21) < 0.001 1.23 (1.20–1.27) < 0.001
Albuminuria 2.14 (2.06–2.22) < 0.001 2.90 (2.66–3.17) < 0.001 2.22 (2.10–2.35) < 0.001 1.78 (1.68–1.88) < 0.001
HbA1c (×1%) 1.00 (0.99–1.02) 0.839 1.00 (0.97–1.03) 0.979 1.01 (0.99–1.03) 0.421 1.00 (0.98–1.02) 0.976
Triglycerides ≥150 mg/dl 1.69 (1.63–1.76) < 0.001 1.85 (1.70–2.02) < 0.001 1.73 (1.64–1.83) < 0.001 1.58 (1.49–1.67) < 0.001
HDL < 40/< 50 mg/dL (Male/Female) 1.41 (1.36–1.46) < 0.001 1.34 (1.23–1.46) < 0.001 1.39 (1.32–1.47) < 0.001 1.48 (1.40–1.56) < 0.001
LDL ≥100 mg/dL 0.88 (0.86–0.91) < 0.001 0.80 (0.74–0.87) < 0.001 0.90 (0.85–0.94) < 0.001 0.91 (0.87–0.96) < 0.001
Blood Pressure ≥ 140/85 mmHg 0.87 (0.84–0.90) < 0.001 1.00 (0.92–1.09) 0.969 0.86 (0.82–0.91) < 0.001 0.84 (0.79–0.88) < 0.001
Smokinga 0.79 (0.74–0.84) < 0.001 0.73 (0.64–0.83) < 0.001 0.81 (0.73–0.90) < 0.001 0.82 (0.71–0.94) 0.004
Model for Albuminuria
Male sex 2.09 (2.02–2.15) < 0.001 1.94 (1.83–2.05) < 0.001 2.30 (2.18–2.42) < 0.001 2.05 (1.93–2.17) < 0.001
Age (×5 years) 1.07 (1.06–1.08) < 0.001 1.02 (1.01–1.04) 0.011 1.08 (1.04–1.13) < 0.001 1.16 (1.11–1.20) < 0.001
BMI (×5 Kg/m2) 1.11 (1.09–1.12) < 0.001 1.14 (1.12–1.17) < 0.001 1.11 (1.09–1.14) < 0.001 1.05 (1.02–1.08) 0.003
eGFR< 60 mL/min/1.73 m2 2.19 (2.11–2.27) < 0.001 2.99 (2.74–3.27) < 0.001 2.27 (2.14–2.40) < 0.001 1.82 (1.72–1.93) < 0.001
HbA1c (×1%) 1.22 (1.20–1.23) < 0.001 1.21 (1.19–1.23) < 0.001 1.24 (1.21–1.27) < 0.001 1.19 (1.16–1.22) < 0.001
Triglycerides ≥150 mg/dl 1.26 (1.22–1.31) < 0.001 1.40 (1.33–1.48) < 0.001 1.19 (1.13–1.26) < 0.001 1.19 (1.11–1.27) < 0.001
HDL < 40/< 50 mg/dL (Male/Female) 1.19 (1.15–1.23) < 0.001 1.18 (1.11–1.24) < 0.001 1.21 (1.14–1.28) < 0.001 1.18 (1.11–1.26) < 0.001
LDL ≥100 mg/dL 0.92 (0.89–0.95) < 0.001 0.89 (0.85–0.94) < 0.001 0.94 (0.89–0.98) 0.010 0.92 (0.87–0.97) 0.002
Blood Pressure ≥ 140/85 mmHg 1.47 (1.42–1.51) < 0.001 1.49 (1.41–1.57) < 0.001 1.45 (1.37–1.52) < 0.001 1.47 (1.38–1.56) < 0.001
Smokinga 1.60 (1.52–1.68) < 0.001 1.58 (1.47–1.70) < 0.001 1.68 (1.54–1.84) < 0.001 1.55 (1.35–1.79) < 0.001
The bold values refers to significant (p < 0.001) associations. Complete case analysis performed including patients for which all data were observed.
Overall group included 115,493 patients: 23,973 (20.8%) with eGFR< 60 mL/min/1.73m2 and 33,598 (29.1% with albuminuria). Group with < 65 years
included 43,945 patients: 2844 (6.5%) with eGFR< 60 mL/min/1.73m2 and 11,401 (25.9%) with albuminuria. Group with 65–75 years included 42,248
patients: 8746 (20.7%) with eGFR< 60 mL/min/1.73m2 and 12,170 (28.8%) with albuminuria. Group with > 75 years included 29,300 patients: 12,383
(42.26%) with eGFR< 60 mL/min/1.73m2 and 10,027 (34.2%) with albuminuria
aModels including smoking status was analysed in 67,276 patients (27,431 with < 65 years, 24,249 with 65–75, and 15,596 with > 75 years)
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other groups. Notably, the QUASAR study [15] showed
that the risk of developing CVD events was 84%
greater in patients with a score of < 15 (incidence rate
ratio: 1.84; 95% CI 1.29–2.62) and 17% higher in those
with a score between 15 and 25 (incidence rate ratio:
1.17; 95% CI 0.93–1.49), as compared with those with
a score of > 25 [15]. Our data extended those observa-
tions indicating that, irrespectively of age, low Q-score
values are a risk factor also for albuminuria, a widely
recognized risk factor for CVD.
Several limitations of the study should be acknowl-
edged. Among these, the potential influence of geriatric
conditions, which may affect quality of care and DKD
outcomes, was not specifically considered; moreover,
we did not take into account that the management of
DKD in elderly patients is complicated by the higher
exposure to drugs’ side effects, including hypoglycemia,
and frequent co-morbidities [28, 34, 56]. Also, we did
not explore the potential associations of the available
classes of drugs with low eGFR and/or albuminuria
phenotypes specifically in the elderly population, al-
though a previous analysis of this cohort showed an
high percentages of patients treated with those drugs
that should be limited or contraindicated by impaired
renal function [57, 58].
Conclusions
In conclusion, in this representative sample of outpatients
with T2DM, DKD prevalence, especially low eGFR, was
very high in subjects > 65 years old. Both low eGFR and
albuminuria were associated with a worst CVD risk factor
profile, although these associations changed according to
the specific outcome examined and were generally attenu-
ated at older ages. Quality of diabetes care was overall
good even at older age, however, when impaired (Q score
< 15), it was associated with a higher risk of albuminuria.
These data indicate that DKD in elderly patients is still a
high-risk condition that deserves full clinical consider-
ation, in order to implement a targeted treatment and im-
prove its outcomes.
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